Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhinomed Limited
  6. Summary
    RNO   AU000000RNO1

RHINOMED LIMITED

(RNO)
End-of-day quote. End-of-day quote Australian Stock Exchange - 12/02
0.295 AUD   +3.51%
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
 SummaryChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
0.27 0.255 0.275 0.285 0.295 Last
132760 31065 100497 586744 50024 Volume
+5.88% -5.56% +7.84% +3.64% +3.51% Change
Estimated financial data (e)
Sales 2020 4,37 M 3,09 M 3,09 M
Net income 2020 -7,27 M -5,14 M -5,14 M
Net cash position 2020 7,17 M 5,07 M 5,07 M
P/E ratio 2020 -1,56x
Yield 2020 -
Sales 2021 4,42 M 3,13 M 3,13 M
Net income 2021 -8,64 M -6,11 M -6,11 M
Net cash position 2021 1,87 M 1,32 M 1,32 M
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 74,9 M 53,2 M 52,9 M
EV / Sales 2020 2,37x
EV / Sales 2021 8,48x
Nbr of Employees -
Free-Float 31,3%
More Financials
Company
Rhinomed Limited is an Australia-based medical technology company that enhancing respiration, sleep, diagnosis of upper respiratory disease, and nasal drug delivery. The CompanyÔÇÖs products include Mute, Turbine, Pronto Sleep, and Pronto Clear. The Mute is a nasal technology that is designed to allow the user to manage the sleep by breathing more and snoring less. The Turbine is a nasal dilator designed to assist... 
More about the company
All news about RHINOMED LIMITED
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
10/26Rhinoswab Clinical Trial Approves At St Vincent's Hospital
CI
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
09/13Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherl..
CI
09/10RHINOMED : to Deliver One Million COVID-19 Nasal Swabs to Australia's Victoria Government
MT
09/09Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the..
CI
08/26Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Sw..
CI
08/26Rhinomed Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/10Rhinomed Limited Receives Purchase Orders and Begun Supplying NSW Health Pathology
CI
05/20RHINOMED : Receives CE Mark for Nasal Swab Product
MT
05/13Rhinomed Limited Announces the Appointment of Associate Professor John Mcbain AO as A N..
CI
05/13RHINOMED : Nasal Swab Product Achieves High Yields, Clinical Study Reveals
MT
More news
News in other languages on RHINOMED LIMITED

- No features available -

More news
Chart RHINOMED LIMITED
Duration : Period :
Rhinomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHINOMED LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Michael Johnson Chief Executive Officer, MD & Executive Director
Sean Slattery Chief Financial Officer & Secretary
Ronald R. Dewhurst Non-Executive Chairman
Brent J. Scrimshaw Independent Non-Executive Director
Eric Knight Independent Non-Executive Director
Sector and Competitors